Share the post "ALEMBIC PHARMACEUTICALS LIMITED’s Quarterly Result and Earnings Report for Q4(Mar 2024) : Sales increased by 7.86 % in YoY and decreased by 6.97 % in QoQ"
Highlights
- Sales over the Year and quarter: The company experienced a substantial growth of 7.86 % in the past year, decrease in net sales/revenue by -6.97 %.
- Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 142.46 %. Marginal increase in other income during this quarter, up by 12.63%.
- Profit over the Year and quarter: Significant improvement in profitability for ALEMBIC PHARMACEUTICALS LIMITED. Notable increase of 16.78 % in net profit Year to Year, ALEMBIC PHARMACEUTICALS LIMITED’s profitability dropped by -1.24 % Quarter to Quarter.
- EPS over the Year and quarter: EPS increased by 16.88 % Year to Year. EPS decreased by -1.2 % in previous quarter. Analysis needed for shareholder value.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 1406.447 Cr | Rs. 1630.568 Cr | Rs. 1516.979 Cr | -6.97 % | + 7.86 % |
| Expenses | Rs. 1194.24 Cr | Rs. 1364.21 Cr | Rs. 1256.92 Cr | -7.86 % | + 5.25 % |
| Operating Profit | Rs. 212.21 Cr | Rs. 266.36 Cr | Rs. 260.06 Cr | -2.37 % | + 22.55 % |
| OPM % | 15.09 % | 16.34 % | 17.14 % | + 0.8 % | + 2.05 % |
| Other Income | Rs. -7.56 Cr | Rs. 2.85 Cr | Rs. 3.21 Cr | + 12.63 % | + 142.46 % |
| Interest | Rs. 14.37 Cr | Rs. 15.17 Cr | Rs. 10.94 Cr | -27.88 % | -23.87 % |
| Depreciation | Rs. 74.12 Cr | Rs. 69.45 Cr | Rs. 69.48 Cr | + 0.04 % | -6.26 % |
| Profit before tax | Rs. 116.16 Cr | Rs. 184.59 Cr | Rs. 182.85 Cr | -0.94 % | + 57.41 % |
| Tax % | 29.24 % | 2.23 % | 2.53 % | + 0.3 % | -26.71 % |
| Net Profit | Rs. 152.6 Cr | Rs. 180.46 Cr | Rs. 178.21 Cr | -1.25 % | + 16.78 % |
| EPS in Rs | Rs. 7.76 | Rs. 9.18 | Rs. 9.07 | -1.2 % | + 16.88 % |
Today, we’re looking at ALEMBIC PHARMACEUTICALS LIMITED’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 7.86 %. However, it did see a marginal slip of -6.97 % from the previous quarter. Expenses decreased slightly by -7.86 % quarter-on-quarter, aligning with the annual rise of 5.25 %. Operating profit, while up 22.55 % compared to last year, faced a quarter-on-quarter dip of -2.37 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 2.05 %, but an expansion of 0.8 % sequentially. Other income rose by 12.63 % compared to the last quarter, despite an annual growth of 142.46 %. Interest expenses dropped significantly by -27.88 % from the previous quarter, yet the year-over-year decrease remains at a moderate -23.87 %. Depreciation costs climbed by 0.04 % quarter-on-quarter, yet on an annual scale, they experienced a reduction of -6.26 %. Profit before tax grew annually by 57.41 % but saw a reduction from the preceding quarter by -0.94 %.
Tax expenses as a percentage of profits decreased slightly by -26.71 % compared to last year, with a more notable quarter-on-quarter increase of 0.3 %. Net profit rose by 16.78 % year-on-year but witnessed a -1.25 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 16.88 % but a quarterly fall of -1.2 %. In summary, ALEMBIC PHARMACEUTICALS LIMITED’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 1406.447 Cr | Rs. 1630.568 Cr | Rs. 1516.979 Cr | -6.97 % | + 7.86 % |
| Expenses | Rs. 1194.24 Cr | Rs. 1364.21 Cr | Rs. 1256.92 Cr | -7.86 % | + 5.25 % |
| Operating Profit | Rs. 212.21 Cr | Rs. 266.36 Cr | Rs. 260.06 Cr | -2.37 % | + 22.55 % |
| Net Profit | Rs. 152.6 Cr | Rs. 180.46 Cr | Rs. 178.21 Cr | -1.25 % | + 16.78 % |
| EPS in Rs | Rs. 7.76 | Rs. 9.18 | Rs. 9.07 | -1.2 % | + 16.88 % |
In reviewing ALEMBIC PHARMACEUTICALS LIMITED’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 7.86 % year-on-year growth, although there was a slight dip of -6.97 % from the previous quarter. Expenses rose by 5.25 % compared to the previous year, with a decrease of -7.86 % quarter-on-quarter. Operating Profit surged by 22.55 % annually, and saw a -2.37 % decrease from the last quarter.
Net Profit showed yearly increase of 16.78 %, and experienced a -1.25 % decrease from the previous quarter. Earnings Per Share (EPS) rose by 16.88 % annually, however dipped by -1.2 % compared to the last quarter. In essence, while ALEMBIC PHARMACEUTICALS LIMITED exhibits strong annual growth indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.
